ArticleEuropean journal of neurology2025
Deceleration Capacity as a Marker of Autonomic Cardiac Modulation in Prodromal and Manifest Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDegenerative parkinsonian syndromes, including the alpha-synucleinopathies (aSYN) Parkinson's disease (PD), and multiple system atrophy (MSA), and the tauopathy progressive supranuclear palsy (PSP), are characterized by motor and non-motor symptoms. The later subsume autonomic dysfunction, which may appear early or progress with the disease. Cardiac dysfunction varies by syndrome and can also occur in isolated REM sleep behavior disorder (iRBD), a prodromal stage of aSYN. Overlapping motor features make early differentiation challenging. Heart rate variability (HRV) analysis is a noninvasive tool for evaluating cardiac autonomic function, with deceleration capacity (DC) as a sensitive parasympathetic marker. This study compares HRV and DC across parkinsonian syndromes to assess their potential in early diagnosis and differentiation.
methodsUsing standardized 30-min resting ECG recordings in the early morning, we analyzed HRV parameters in five groups: iRBD (n = 10), PD (n = 10), MSA (n = 10), PSP (n = 9), and healthy controls (HC, n = 10). Evaluated HRV parameters included HRV index (HRVI), reflecting overall variability, and DC.
resultsAs expected, DC was significantly lower in MSA (3.82 ± 1.38) and unexpectedly even lower in PSP (3.19 ± 2.77), compared to HC (9.66 ± 4.67) and PD (7.55 ± 2.48). These findings are novel for PSP. HRVI was significantly reduced in PSP, while other HRV parameters showed no significant differences.
conclusionsDeceleration capacity (DC) reduction in MSA and PSP suggests pronounced cardiac parasympathetic dysfunction. DC may support differentiation between PD and atypical syndromes, but larger studies are needed for validation. Given the impact of autonomic dysfunction on quality of life and mortality, comprehensive autonomic testing should be included in the diagnostic workup.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.